Korean Journal of Clinical Pharmacy

Table. 1.

Table. 1. Table 1

Baseline characteristics of included studies

Study name	Study design	Primary targets	Patients number-Safety		Intervention	Control	Fold change

			Intervention	Control			C_max	AUC
Poggesi et al. 2019 (11)	RCT	FGFR	17	19	Erdaftinib + Itraconazole	Erdaftinib	1.05	1.34
Abbas et al. 2011 (12)	RCT	EGFR	23	22	Neratinib + Ketoconazole	Neratinib	3.63	5.16
Martin et al. 2011 (13)	RCT	VEGFR-2 /EGFR	15	15	Vandetanib + Itraconazole	Vandetanib	0.99	1.14
Dutreix et al. 2004 (14)	RCT	ABL/BCR-ABL/ ARG	14	14	Imatinib + Ketoconazole	Imatinib	1.29	1.38
Dymond et al. 2017 (15)	Partially randomized	MEK1/2	24	26	Selumetinib +Itraconazole	Selumetinib	1.18	1.49
Pithavala et al. 2012 (16)	RCT	VEGFR1-3	29	32	Axitinib + Ketoconazole	Axitinib	1.50	2.06
Shumaker et al. 2015 (17)	RCT	VEGFR1-3	18	18	Lenvatinib+ Ketoconazole	Lenvatinib	1.21	1.16
Liu et al. 2021 (18)	RCT	EGFR-2	18	18	Pyrotinib +Itraconazole	Pyrotinib	3.71	11.12
Sonnichsen et al. 2011 (19)	RCT	Src/Abl	24	24	Bosutinib + Ketoconazole	Bosutinib	5.18	8.64
Narasimhan et al. 2013 (20)	RCT	BCR/ABL	23	23	Ponatinib + Ketoconazole	Ponatinib	1.46	1.78
Li et al. 2018 (21)	RCT	FLT3	31	31	Quizartinib + Ketoconazole	Quizartinib	1.16	1.94

AUC, area under the curve; Cmax, maximum serum concentration; EGFR, Epidermal growth factor receptor FGFR, fibroblast growth factor receptor; MEK, Mitogen-activated protein kinase kinase RCT, randomized clinical trial; VEGFR, Vascular Endothelial Growth Factor;

Korean J Clin Pharm 2024;34:71-8 https://doi.org/10.24304/kjcp.2024.34.1.71